{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:21:11Z","timestamp":1784168471233,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Daiichi Sankyo Europe"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Leducq Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Centre for Heart Research"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS\/Pfizer"},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"name":"Portola"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ijcard.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T01:34:09Z","timestamp":1592703249000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies"],"prefix":"10.1016","volume":"318","author":[{"given":"Giuseppe","family":"Patti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Pecen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius Constantin","family":"Manu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Rohla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele De","family":"Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.06.010_bb0005","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0010","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/jama.2011.659","article-title":"Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation","volume":"305","author":"Conen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0015","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ahj.2007.10.004","article-title":"Atrial fibrillation and obesity\u2014results of a meta-analysis","volume":"155","author":"Wanahita","year":"2008","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0025","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/eurheartj\/ehn324","article-title":"Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years","volume":"29","author":"Tsang","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/eurheartj\/ehs217","article-title":"Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry","volume":"34","author":"Angeras","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archinte.165.1.55","article-title":"The obesity paradox: body mass index and outcomes in patients with heart failure","volume":"165","author":"Curtis","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0040","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0045","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","article-title":"The \u2018obesity paradox\u2019 in atrial fibrillation: observations from the ARISTOTLE (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial","volume":"37","author":"Sandhu","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjcard.2016.04.013","article-title":"Relation of nonvalvular atrial fibrillation to body mass index (from the SPORTIF trials)","volume":"118","author":"Proietti","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0055","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/STROKEAHA.116.015984","article-title":"Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials","volume":"48","author":"Proietti","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0060","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis","author":"Zhou","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.amjcard.2018.11.019","article-title":"Impact of body mass index on outcomes in the edoxaban versus warfarin therapy groups in patients underwent cardioversion of atrial fibrillation (from ENSURE-AF)","volume":"123","author":"Lip","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacep.2015.12.001","article-title":"Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry","volume":"2","author":"Pandey","year":"2016","journal-title":"JACC Clin. Electrophysiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004006","article-title":"Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review","volume":"5","author":"Zhu","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0080","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0085","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2019.10.035","article-title":"Patients with higher body mass index treated with direct \/ novel oral anticoagulants (DOAC\/NOAC) for atrial fibrillation experience worse clinical outcomes","volume":"301","author":"Lucijanic","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","article-title":"Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective Dresden NOAC Registry (NCT01588119)","volume":"262","author":"Tittl","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0105","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0115","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0120","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.06.010_bb0125","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH03-01-0014","article-title":"Association between obesity and a prothrombotic state: the Framingham Offspring Study","volume":"91","author":"Rosito","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13184","article-title":"Obesity and risk of bleeding: the SMART study","volume":"14","author":"Braekkan","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0135","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/eurheartj\/ehy861","article-title":"Relationship between body mass index and outcome in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Boriani","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2018.06.098","article-title":"Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - a pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries","volume":"270","author":"Patti","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","article-title":"The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review","volume":"106","author":"De Caterina","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0150","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2016.10.069","article-title":"Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF","volume":"69","author":"Patti","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0160","first-page":"6","article-title":"Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF thromboembolic events-European registry in atrial fibrillation)","volume":"23","author":"Patti","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0165","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","article-title":"Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation","volume":"132","author":"Patti","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2020.06.010_bb0170","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.amjcard.2019.08.030","article-title":"Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes (from the START-ANTIPLATELET registry)","volume":"124","author":"Calabr\u00f2","year":"2019","journal-title":"Am. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732033388X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732033388X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:49:41Z","timestamp":1759092581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732033388X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":34,"alternative-id":["S016752732033388X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.06.010","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}